Nasopharyngeal Carcinoma
Conditions
Brief summary
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy
Interventions
DRUGAnlotinib
All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* biopsy proved nasopharyngeal carcinoma; * stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy; * 18 years or older; without other malignancy; * proper functioning of the major organs.
Exclusion criteria
* allergic to anlotinib; * female within gestation period or lactation; * patients received drug of other clinical trial within 4 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease control rate | 30 months | disease control rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate | 30 months | overall response rate |
| progression-free survival | 30 months | progression-free survival |
| overall survival | 30 months | overall survival |
| duration of response | 30 months | duration of response |
Countries
China
Outcome results
None listed